Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Galectin Therapeutics Inc. for potential violations of federal securities laws following a significant drop in the company's stock price after FDA communications regarding its drug development program [1][3]. Group 1: Company Developments - Galectin Therapeutics announced on December 19, 2025, that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on December 19, 2025, reflecting investor concerns regarding the unresolved aspects of the clinical trial design [3]. Group 3: Legal Context - Levi & Korsinsky, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [4].